Analysts expect Grifols SA to report Q2 2026 revenue of approximately $1.95 billion and earnings per share of $0.27, with the stock currently trading near $7.80 compared to an average analyst price target of $10.87.
The primary focus for investors in this report is the company’s deleveraging progress, as the market monitors whether the net leverage ratio will continue its descent from the 4.2x recorded earlier this year toward management's 3.0x target.
Grifols has recently addressed liquidity concerns by refinancing all debt maturities through 2027 and reporting a significant turnaround in free cash flow, which turned positive at €91 million for the first half of 2026. However, the company continues to navigate the aftermath of accounting allegations from short-sellers, making sustained margin expansion and operational efficiency in its new Biopharma structure critical for restoring long-term investor confidence.